KennethWDawesMD

Dermatology • Indianapolis, IN

Physician

Join to view full profile

Dr. Dawes is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Dawes' full profile

Already have an account?

Office
7910 N Shadeland Ave
Indianapolis, IN 46250
Phone+1 317-516-5000

Fax+1 317-516-5146

Education & Training

Indiana University School of MedicineResidency, Dermatology, 1992 - 1995
Ascension St Vincent Hospital IndianapolisResidency, Internal Medicine, 1989 - 1992
Indiana University School of MedicineClass of 1989

Certifications & Licensure

IN State Medical License 1990 - 2025
American Board of Dermatology Dermatology

Awards, Honors, & Recognition

Indianapolis Monthly Castle Connolly, 2011, 2013
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Fellow (FAAD) American Academy of Dermatology

Clinical Trials

A Study of Multiple Doses of AbGn-168H by Intravenous Infusion in Patients With Moderate to Severe Chronic Plaque Psoriasis Start of enrollment: 2014 May 01
Completed
Phase 2
A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis Start of enrollment: 2015 Dec 01
Completed
Phase 3
Finasteride Treatment of Severe Nodulocystic Acne Start of enrollment: 2015 Jul 01
Completed
Phase 2
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis Start of enrollment: 2019 Aug 12
Active, not recruiting
Phase 3
NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) Start of enrollment: 2021 Sep 20
Completed
Phase 2
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

20 citations
Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial.
Ellen J Kim, Aaron R Mangold, Jennifer A DeSimone, Henry K Wong, Lucia Seminario-Vidal
JAMA Dermatology. 2022-09-01

Press Mentions

Timber Pharmaceuticals Announces First Patients Enrolled in Phase 3 ASCEND Clinical Trial Evaluating TMB-001 in Congenital IchthyosisJune 23rd, 2022

Professional Memberships

American Academy of Dermatology - AAD
Fellow